{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:38:30Z","timestamp":1792633110303,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Bardet\u2013Biedl syndrome (BBS) is a rare genetic disease caused by impaired cilium function and characterized by a plethora of symptoms, including hyperphagia and early-onset obesity, that negatively affect patient and caregiver quality of life. Here, we assessed real-world patient expectations and experiences before and during treatment with setmelanotide, a melanocortin-4 receptor agonist shown to reduce hunger and body weight in patients with BBS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>An online survey was conducted to capture the real-world experience of patients with BBS and their caregivers regarding setmelanotide treatment and the use of a specialist nurse support service aimed at educating patients and their caregivers, and enabling them to administer injections independently. The survey was administered between January 2024 and May 2024 to participants who began treatment between June 2023 and December 2023 at a single center in Germany.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 35 respondents, 10 were pediatric patients, 13 were adult patients, and 12 were caregivers. Prior to treatment, the most commonly reported symptoms by pediatric patients and caregivers were insatiable hunger (80% and 83%, respectively) and obesity (50% and 92%, respectively); for adult patients, key symptoms were vision loss (92%) and obesity (69%). Setmelanotide reduced feelings of insatiable hunger and had a positive effect on body weight: \u2265 92% of respondents across survey groups reported feeling less hunger, feeling satiated after meals, and a stable body weight or weight loss (mean BMI z-score\u2009\u00b1\u2009SD at start: 3.12\u2009\u00b1\u20090.89, change after 6 months: \u22120.47\u2009\u00b1\u20090.37). Improvements in mobility, mood, and behavior were also reported. The specialist nurse support service was rated excellent by all respondents. The personalized approach contributed to high patient and caregiver satisfaction, enabled most of them to administer the drug independently, and ensured high treatment adherence, without any patients discontinuing setmelanotide treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Based on this real-world survey of patients with BBS and their caregivers, setmelanotide improved key symptoms related to insatiable hunger and obesity. Personalized multidimensional nursing support at the start of treatment can help address unmet support needs in BBS and may contribute to high rates of treatment satisfaction and adherence.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03835-9","type":"journal-article","created":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T18:35:21Z","timestamp":1749407721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Patient and caregiver experiences with a patient-support program for setmelanotide treatment of patients with Bardet\u2013Biedl syndrome"],"prefix":"10.1186","volume":"20","author":[{"given":"Ilja","family":"Finkelberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna M.","family":"Polichronidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"H\u00fchne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Brensing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinem","family":"Karaterzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Jaegers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"G\u00e4ckler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Pape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0918-9204","authenticated-orcid":false,"given":"Metin","family":"Cetiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,8]]},"reference":[{"key":"3835_CR1","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1038\/s41431-024-01634-7","volume":"32","author":"H Dollfus","year":"2024","unstructured":"Dollfus H, Lilien MR, Maffei P, Verloes A, Muller J, Bacci GM, et al. Bardet-Biedl syndrome improved diagnosis criteria and management: inter European reference networks consensus statement and recommendations. Eur J Hum Genet. 2024;32:1347\u201360.","journal-title":"Eur J Hum Genet"},{"key":"3835_CR2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1055\/a-2251-5382","volume":"236","author":"M Cetiner","year":"2024","unstructured":"Cetiner M, Bergmann C, Bettendorf M, Faust J, G\u00e4ckler A, Gillissen B, et al. Improved care and treatment options for patients with hyperphagia-associated obesity in Bardet-Biedl syndrome. [Article in German]. Klin Padiatr. 2024;236:269\u201379.","journal-title":"Klin Padiatr"},{"key":"3835_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/TCRM.S338653","volume":"19","author":"A Melluso","year":"2023","unstructured":"Melluso A, Secondulfo F, Capolongo G, Capasso G, Zacchia M. Bardet-Biedl syndrome: current perspectives and clinical outlook. Ther Clin Risk Manag. 2023;19:115\u201332.","journal-title":"Ther Clin Risk Manag"},{"key":"3835_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fped.2018.00023","volume":"6","author":"E Forsythe","year":"2018","unstructured":"Forsythe E, Kenny J, Bacchelli C, Beales PL. Managing Bardet-Biedl syndrome\u2013 now and in the future. Front Pediatr. 2018;6:23.","journal-title":"Front Pediatr"},{"key":"3835_CR5","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1136\/jmg.36.6.437","volume":"36","author":"PL Beales","year":"1999","unstructured":"Beales PL, Elcioglu N, Woolf AS, Parker D, Flinter FA. New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey. J Med Genet. 1999;36:437\u201346.","journal-title":"J Med Genet"},{"key":"3835_CR6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ajmg.a.30406","volume":"132A","author":"SJ Moore","year":"2005","unstructured":"Moore SJ, Green JS, Fan Y, Bhogal AK, Dicks E, Fernandez BA, et al. Clinical and genetic epidemiology of Bardet-Biedl syndrome in newfoundland: a 22-year prospective, population-based, cohort study. Am J Med Genet A. 2005;132A:352\u201360.","journal-title":"Am J Med Genet A"},{"key":"3835_CR7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/j.1399-0004.1989.tb03378.x","volume":"36","author":"TI Farag","year":"1989","unstructured":"Farag TI, Teebi AS. High incidence of Bardet Biedl syndrome among the bedouin. Clin Genet. 1989;36:463\u20134.","journal-title":"Clin Genet"},{"key":"3835_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/ejhg.2012.115","volume":"21","author":"E Forsythe","year":"2013","unstructured":"Forsythe E, Beales PL. Bardet-Biedl syndrome. Eur J Hum Genet. 2013;21:8\u201313.","journal-title":"Eur J Hum Genet"},{"key":"3835_CR9","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13023-023-02723-4","volume":"18","author":"E Forsythe","year":"2023","unstructured":"Forsythe E, Mallya UG, Yang M, Huber C, Cala ML, Greatsinger A, et al. Burden of hyperphagia and obesity in Bardet-Biedl syndrome: a multicountry survey. Orphanet J Rare Dis. 2023;18:182.","journal-title":"Orphanet J Rare Dis"},{"key":"3835_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13023-023-02692-8","volume":"18","author":"E Forsythe","year":"2023","unstructured":"Forsythe E, Mallya UG, Yang M, Huber C, Cala ML, Greatsinger A, et al. Caregiver burden in Bardet-Biedl syndrome: findings from the CARE-BBS study. Orphanet J Rare Dis. 2023;18:181.","journal-title":"Orphanet J Rare Dis"},{"key":"3835_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13023-022-02602-4","volume":"18","author":"E Forsythe","year":"2023","unstructured":"Forsythe E, Haws RM, Argente J, Beales P, Martos-Moreno G\u00c1, Dollfus H, et al. Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial results. Orphanet J Rare Dis. 2023;18:12.","journal-title":"Orphanet J Rare Dis"},{"key":"3835_CR12","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1001\/jama.289.14.1813","volume":"289","author":"JB Schwimmer","year":"2003","unstructured":"Schwimmer JB, Burwinkle TM, Varni JW. Health-related quality of life of severely obese children and adolescents. JAMA. 2003;289:1813\u20139.","journal-title":"JAMA"},{"key":"3835_CR13","doi-asserted-by":"publisher","first-page":"e12703","DOI":"10.1111\/ijpo.12703","volume":"16","author":"J Pomeroy","year":"2021","unstructured":"Pomeroy J, Krentz AD, Richardson JG, Berg RL, Van Wormer JJ, Haws RM. Bardet-Biedl syndrome: weight patterns and genetics in a rare obesity syndrome. Pediatr Obes. 2021;16:e12703.","journal-title":"Pediatr Obes"},{"key":"3835_CR14","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.biopsych.2022.01.018","volume":"91","author":"IS Farooqi","year":"2022","unstructured":"Farooqi IS. Monogenic obesity syndromes provide insights into the hypothalamic regulation of appetite and associated behaviors. Biol Psychiatry. 2022;91:856\u20139.","journal-title":"Biol Psychiatry"},{"key":"3835_CR15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/MED.0000000000000798","volume":"30","author":"CM Trapp","year":"2023","unstructured":"Trapp CM, Censani M. Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity. Curr Opin Endocrinol Diabetes Obes. 2023;30:136\u201340.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"3835_CR16","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1111\/dom.14133","volume":"22","author":"R Haws","year":"2020","unstructured":"Haws R, Brady S, Davis E, Fletty K, Yuan G, Gordon G, et al. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome. Diabetes Obes Metab. 2020;22:2133\u201340.","journal-title":"Diabetes Obes Metab"},{"key":"3835_CR17","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S2213-8587(22)00277-7","volume":"10","author":"AM Haqq","year":"2022","unstructured":"Haqq AM, Chung WK, Dollfus H, Haws RM, Martos-Moreno G\u00c1, Poitou C, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstr\u00f6m syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes Endocrinol. 2022;10:859\u201368.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3835_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S2213-8587(24)00273-0","volume":"13","author":"J Argente","year":"2025","unstructured":"Argente J, Verge CF, Okorie U, Fennoy I, Kelsey MM, Cokkinias C, et al. Setmelanotide in patients aged 2\u20135 years with rare MC4R pathway-associated obesity (VENTURE): a 1-year, open-label, multicenter, phase 3 trial. Lancet Diabetes Endocrinol. 2025;13:29\u201337.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3835_CR19","unstructured":"IMCIVREE\u00ae summary of product characteristics. 2024. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2024\/20240726163372\/anx_163372_en.pdf. Accessed September 2024."},{"key":"3835_CR20","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40265-021-01470-9","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A. Setmelanotide: first approval. Drugs. 2021;81:397\u2013403.","journal-title":"Drugs"},{"key":"3835_CR21","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s13023-024-03400-w","volume":"19","author":"M Cetiner","year":"2024","unstructured":"Cetiner M, Finkelberg I, Schiepek F, Pape L, Hirtz R, B\u00fcscher AK. Ultrasound evaluation of kidney and liver involvement in Bardet-Biedl syndrome. Orphanet J Rare Dis. 2024;19:425.","journal-title":"Orphanet J Rare Dis"},{"key":"3835_CR22","doi-asserted-by":"crossref","unstructured":"Morris S, Hudson E, Bloom L, Chitty LS, Fulop NJ, Hunter A et al. Co-ordinated care for people affected by rare diseases: the CONCORD mixed-methods study. Health Soc Care Deliv Res. 2022;10(5).","DOI":"10.3310\/LNZZ5321"},{"key":"3835_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13023-020-01660-w","volume":"16","author":"MK Depping","year":"2021","unstructured":"Depping MK, Uhlenbusch N, von Kodolistsch Y, Klose HFE, Mautner V-F, L\u00f6we B. Supportive care needs of patients with rare chronic diseases: multi-method, cross-sectional study. Orphanet J Rare Dis. 2021;16:44.","journal-title":"Orphanet J Rare Dis"},{"key":"3835_CR24","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jamadermatol.2023.3251","volume":"159","author":"D Rodriguez","year":"2023","unstructured":"Rodriguez D, Kwatra SG, Dias-Barbosa C, Zeng F, Jabbar Lopez ZK, Piketty C, et al. Patient perspectives on living with severe prurigo nodularis. JAMA Dermatol. 2023;159:1205\u201312.","journal-title":"JAMA Dermatol"},{"key":"3835_CR25","doi-asserted-by":"crossref","unstructured":"Heymsfield SB, Avena NM, Baier L, Brantley P, Bray GA, Burnett LC et al. Hyperphagia: current concepts and future directions proceedings of the 2nd international conference on hyperphagia. Obesity (Silver Spring). 2014;22 Suppl 1:S1\u201317.","DOI":"10.1002\/oby.20646"},{"key":"3835_CR26","doi-asserted-by":"crossref","unstructured":"Beales PL, Cetiner M, Haqq AM, Miller J, Shoemaker AH, Valverde D et al. Hyperphagia in Bardet\u2013Biedl syndrome: pathophysiology, burden, and management. Obes Rev. 2025;e13915.","DOI":"10.1111\/obr.13915"},{"key":"3835_CR27","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1007\/s12325-023-02443-y","volume":"40","author":"C Ervin","year":"2023","unstructured":"Ervin C, Norcross L, Mallya UG, Fehnel S, Mittleman RS, Webster M, et al. Interview-based patient- and caregiver-reported experiences of hunger and improved quality of life with setmelanotide treatment in Bardet-Biedl syndrome. Adv Ther. 2023;40:2394\u2013411.","journal-title":"Adv Ther"},{"key":"3835_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/NHH.0000000000001064","volume":"40","author":"K Sexson","year":"2022","unstructured":"Sexson K, Lindauer A, Harvath TA. Administration of subcutaneous injections: nurses can help family caregivers enhance their knowledge, experience, and skill in managing injectable treatments. Home Healthc now. 2022;40:70\u20134.","journal-title":"Home Healthc now"},{"key":"3835_CR29","first-page":"7","volume":"8","author":"M Schlangen","year":"2023","unstructured":"Schlangen M, Heuing K. Rare diseases in Germany\u2013 developments in the status of medical care. J Health Monit. 2023;8:7\u201316.","journal-title":"J Health Monit"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03835-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03835-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03835-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T18:35:23Z","timestamp":1749407723000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03835-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,8]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3835"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03835-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,8]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the local ethics committee (reference number 24-11708-BO). Informed consent was obtained from all participants and\/or parents\/legal guardians when appropriate. This study was conducted in accordance with the Declaration of Helsinki on Biomedical Studies Involving Human Subjects and published under the study code UME-ID-12056 in the study register of the University Medical Center Essen ().","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TH and AG received travel expenses from Rhythm Pharmaceuticals. LP received payments for lectures, expert testimony and travel expenses from Rhythm Pharmaceuticals. MC received grant support for observational studies, payments for lectures and expert testimony, consulting fees and travel expenses from Rhythm Pharmaceuticals. IF, IMP, PB, SK and JJ declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"290"}}